{"id":13943,"date":"2023-08-23T08:31:00","date_gmt":"2023-08-23T12:31:00","guid":{"rendered":"https:\/\/www.rigicon.com\/uncategorized\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment-2\/"},"modified":"2023-08-23T08:31:00","modified_gmt":"2023-08-23T12:31:00","slug":"new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment","status":"publish","type":"post","link":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","title":{"rendered":"Un nuevo estudio confirma los primeros resultados de seguridad para Rigicon ContiClassic\u00ae: Esf\u00ednter Urinario Artificial, en el tratamiento masculino Incontinencia Urinaria de Esfuerzo"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\">Estamos orgullosos de anunciar la publicaci\u00f3n del art\u00edculo estudio cl\u00ednico de &#8220;Primeros resultados de seguridad para Rigicon ContiClassic: Esf\u00ednter Urinario Artificial&#8221;. Este estudio arroja luz sobre el perfil de seguridad de Rigicon ContiClassic en el tratamiento de incontinencia urinaria de esfuerzo (SUI) masculino y lo posiciona como una opci\u00f3n innovadora comparable junto con el soluciones existente.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Introducido en el mercado internacional hace apenas dos a\u00f1os, el Rigicon ContiClassic Esf\u00ednter Urinario Artificial ha llamado r\u00e1pidamente la atenci\u00f3n como una opci\u00f3n de tratamiento viable para los hombres que luchan contra incontinencia urinaria de esfuerzo.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">El estudio se centr\u00f3 en la demograf\u00eda de los pacientes, las complejidades quir\u00fargicas y las causas subyacentes de la incontinencia, revelando una eficacia encomiable en una cohorte diversa de pacientes. En particular, los participantes ten\u00edan una edad media de 68,3 a\u00f1os, y el incontinencia urinaria relacionado con el post-prostatectom\u00eda radical represent\u00f3 el 58,6 % de las implantaciones. Es alentador que el estudio no inform\u00f3 casos de infecciones o complicaciones significativos. Lo m\u00e1s destacado del estudio fue el c\u00e1lculo de Kaplan-Meier, que demostr\u00f3 una impresionante tasa de supervivencia del 93,2 % en el hito de los 12 meses.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La reconocida autoridad en urolog\u00eda, el Dr. Steven K. Wilson, elogi\u00f3 los hallazgos del estudio y afirm\u00f3: &#8220;El Rigicon ContiClassic representa un paso importante para abordar el incontinencia urinaria de esfuerzo masculino. Su dise\u00f1o innovador y sus resultados de seguridad comparables lo posicionan como una opci\u00f3n valiosa para pacientes que busca un soluciones eficaz&#8221;.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acerca de Incontinencia Urinaria<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Incontinencia Urinaria (UI) es la p\u00e9rdida involuntaria de orina. Los pacientes que padecen Incontinencia Urinaria no pueden controlar la liberaci\u00f3n de orina del vejiga. Si bien Incontinencia Urinaria de Esfuerzo es el tipo m\u00e1s com\u00fan, existen diferentes tipos de incontinencia urinaria. Incontinencia Urinaria de Esfuerzo es la p\u00e9rdida inesperada de orina cuando se produce una presi\u00f3n exterior con actividades como levantar objetos pesados, toser, estornudar, re\u00edr o hacer ejercicio. Esta presi\u00f3n exterior hace que el ya debilitado vejiga pierda orina.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los esf\u00ednteres urinarios debilitados pueden ser causados \u200b\u200bpor: Cirug\u00eda en el \u00e1rea p\u00e9lvica o el pr\u00f3stata, lesi\u00f3n en el uretra, medicamentos, sobrepeso, cambios con la edad, otras causas. Incontinencia Urinaria es un problema importante que afecta a decenas de millones de pacientes. Se estima que la IU afecta a 1 de cada 10 hombres, y su prevalencia est\u00e1 asociada con el envejecimiento.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Los hombres con Incontinencia Urinaria tienen una tasa m\u00e1s alta de depresi\u00f3n y son m\u00e1s propensos a disminuir la participaci\u00f3n en actividades (por ejemplo, disminuir las horas de trabajo, cambiar de empleo o jubilarse anticipadamente voluntariamente).<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">La mayor\u00eda de los pacientes que experimentan incontinencia urinaria semanalmente no buscan atenci\u00f3n m\u00e9dica. Muchos de los que buscaron tratamiento creen que no se les proporcion\u00f3 ninguno y muchos de los que recibieron tratamiento siguen teniendo s\u00edntomas preocupantes.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Acerca de Esf\u00ednter Urinario Artificial<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Esf\u00ednter Urinario Artificial (AUS) es un dispositivo m\u00e9dico dise\u00f1ado espec\u00edficamente para tratar incontinencia urinaria. Esf\u00ednter Urinario Artificial es una opci\u00f3n de tratamiento quir\u00fargico cuando las opciones de tratamiento conductual o no quir\u00fargico fallan.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\">AUS imitar\u00e1 el papel de un esf\u00ednter urinario sano (los dos m\u00fasculos que controlan la salida de la orina desde el vejiga hasta el uretra) AUS cerrar\u00e1 el uretra evitando la p\u00e9rdida de orina. El paciente apretar\u00e1 un bomba ubicado en su escroto para liberar el manguito sobre el uretra y anular. El manguito volver\u00e1 a su estado cerrado en aproximadamente 2 minutos para evitar p\u00e9rdidas de orina despu\u00e9s de orinar.<br>El esf\u00ednter urinario artificial se considera ampliamente como el est\u00e1ndar de oro para el tratamiento de Incontinencia Urinaria.<\/p>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Sobre nosotros<\/strong><\/p>\n\n\n\n<p class=\"wp-block-paragraph\">Rigicon se especializa en la investigaci\u00f3n, desarrollo y fabricaci\u00f3n de soluciones de urolog\u00eda prot\u00e9sica innovadores con 30 a\u00f1os de experiencia en Urolog\u00eda. Nos centramos en crear una cartera completa de productos para ur\u00f3logos de todo el mundo. Comprometidos con mejorar la calidad de vida para pacientes, Rigicon se enfoca en brindar tratamientos de vanguardia que abordan diversas afecciones urol\u00f3gicas, incluidas disfunci\u00f3n er\u00e9ctil y incontinencia urinaria.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Estamos orgullosos de anunciar la publicaci\u00f3n del art\u00edculo estudio cl\u00ednico de &#8220;Primeros resultados de seguridad para Rigicon ContiClassic: Esf\u00ednter Urinario Artificial&#8221;. Este estudio arroja luz sobre el perfil de seguridad de Rigicon ContiClassic en el tratamiento de incontinencia urinaria de esfuerzo (SUI) masculino y lo posiciona como una opci\u00f3n innovadora comparable junto con el soluciones [&hellip;]<\/p>\n","protected":false},"author":0,"featured_media":1295,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_memberships_contains_paid_content":false,"footnotes":""},"categories":[819],"tags":[],"class_list":["post-13943","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-comunicados-de-prensa"],"acf":{"ce_paper_title":"","ce_year":"","ce_journal":"","ce_doi":"","ce_summary":"","ce_authors":"","ce_objective":"","ce_key_findings":"","ce_conclusion":"","ce_clinical_relevance":"","ce_pdf":null,"ce_logos":null,"ce_featured":false,"ce_keywords":""},"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.9 (Yoast SEO v27.9) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>ContiClassic AUS Safety Outcomes Study | Rigicon<\/title>\n<meta name=\"description\" content=\"Rigicon ContiClassic\u00ae El estudio destaca una tasa de supervivencia del 93,2% a los 12 meses, sin infecciones ni complicaciones mayores, lo que confirma su seguridad en el tratamiento de la IUE masculina.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Un nuevo estudio confirma los primeros resultados de seguridad para Rigicon ContiClassic\u00ae: Esf\u00ednter Urinario Artificial, en el tratamiento masculino Incontinencia Urinaria de Esfuerzo\" \/>\n<meta property=\"og:description\" content=\"Rigicon ContiClassic\u00ae El estudio destaca una tasa de supervivencia del 93,2% a los 12 meses, sin infecciones ni complicaciones mayores, lo que confirma su seguridad en el tratamiento de la IUE masculina.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/\" \/>\n<meta property=\"og:site_name\" content=\"Rigicon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/rigiconurology\/\" \/>\n<meta property=\"article:published_time\" content=\"2023-08-23T12:31:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1440\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@rigiconurology\" \/>\n<meta name=\"twitter:site\" content=\"@rigiconurology\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Un nuevo estudio confirma los primeros resultados de seguridad para Rigicon ContiClassic\u00ae: Esf\u00ednter Urinario Artificial, en el tratamiento masculino Incontinencia Urinaria de Esfuerzo\",\"datePublished\":\"2023-08-23T12:31:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\"},\"wordCount\":738,\"publisher\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"articleSection\":[\"Comunicados de Prensa\"],\"inLanguage\":\"es-ES\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\",\"name\":\"ContiClassic AUS Safety Outcomes Study | Rigicon\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"datePublished\":\"2023-08-23T12:31:00+00:00\",\"description\":\"Rigicon ContiClassic\u00ae El estudio destaca una tasa de supervivencia del 93,2% a los 12 meses, sin infecciones ni complicaciones mayores, lo que confirma su seguridad en el tratamiento de la IUE masculina.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#breadcrumb\"},\"inLanguage\":\"es-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"contentUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2023\\\/08\\\/press-releases-detail-page-classic-aus-d-1.png\",\"width\":1440,\"height\":720},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/comunicados-de-prensa\\\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Inicio\",\"item\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Un nuevo estudio confirma los primeros resultados de seguridad para Rigicon ContiClassic\u00ae: Esf\u00ednter Urinario Artificial, en el tratamiento masculino Incontinencia Urinaria de Esfuerzo\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/\",\"name\":\"Rigicon\",\"description\":\"Innovative Urological Solutions\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/#organization\"},\"alternateName\":\"Innovative Urological Solutions\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/#organization\",\"name\":\"Rigicon, Inc.\",\"alternateName\":\"Innovative Urological Solutions\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es-ES\",\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"contentUrl\":\"https:\\\/\\\/www.rigicon.com\\\/wp-content\\\/uploads\\\/2024\\\/07\\\/cropped-Logo-Square-Kopya.jpg\",\"width\":512,\"height\":512,\"caption\":\"Rigicon, Inc.\"},\"image\":{\"@id\":\"https:\\\/\\\/www.rigicon.com\\\/es\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/x.com\\\/rigiconurology\",\"https:\\\/\\\/www.instagram.com\\\/rigiconurology\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@Rigicon\\\/podcasts\",\"https:\\\/\\\/www.youtube.com\\\/Rigicon\",\"https:\\\/\\\/www.threads.net\\\/@rigiconurology\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/rigicon\\\/\"],\"description\":\"Rigicon is a global provider of innovative, diverse, and complete portfolio of prosthetic urology options.\",\"email\":\"operations@rigicon.com\",\"telephone\":\"+1 (888) 202-9790\",\"legalName\":\"Rigicon, Inc.\",\"vatID\":\"81-3545645\",\"taxID\":\"81-3545645\",\"duns\":\"045247683\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ContiClassic AUS Safety Outcomes Study | Rigicon","description":"Rigicon ContiClassic\u00ae El estudio destaca una tasa de supervivencia del 93,2% a los 12 meses, sin infecciones ni complicaciones mayores, lo que confirma su seguridad en el tratamiento de la IUE masculina.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","og_locale":"es_ES","og_type":"article","og_title":"Un nuevo estudio confirma los primeros resultados de seguridad para Rigicon ContiClassic\u00ae: Esf\u00ednter Urinario Artificial, en el tratamiento masculino Incontinencia Urinaria de Esfuerzo","og_description":"Rigicon ContiClassic\u00ae El estudio destaca una tasa de supervivencia del 93,2% a los 12 meses, sin infecciones ni complicaciones mayores, lo que confirma su seguridad en el tratamiento de la IUE masculina.","og_url":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","og_site_name":"Rigicon","article_publisher":"https:\/\/www.facebook.com\/rigiconurology\/","article_published_time":"2023-08-23T12:31:00+00:00","og_image":[{"width":1440,"height":720,"url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_creator":"@rigiconurology","twitter_site":"@rigiconurology","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#article","isPartOf":{"@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/"},"author":{"name":"","@id":""},"headline":"Un nuevo estudio confirma los primeros resultados de seguridad para Rigicon ContiClassic\u00ae: Esf\u00ednter Urinario Artificial, en el tratamiento masculino Incontinencia Urinaria de Esfuerzo","datePublished":"2023-08-23T12:31:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/"},"wordCount":738,"publisher":{"@id":"https:\/\/www.rigicon.com\/es\/#organization"},"image":{"@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","articleSection":["Comunicados de Prensa"],"inLanguage":"es-ES"},{"@type":"WebPage","@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","url":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/","name":"ContiClassic AUS Safety Outcomes Study | Rigicon","isPartOf":{"@id":"https:\/\/www.rigicon.com\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage"},"image":{"@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage"},"thumbnailUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","datePublished":"2023-08-23T12:31:00+00:00","description":"Rigicon ContiClassic\u00ae El estudio destaca una tasa de supervivencia del 93,2% a los 12 meses, sin infecciones ni complicaciones mayores, lo que confirma su seguridad en el tratamiento de la IUE masculina.","breadcrumb":{"@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#breadcrumb"},"inLanguage":"es-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/"]}]},{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#primaryimage","url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","contentUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","width":1440,"height":720},{"@type":"BreadcrumbList","@id":"https:\/\/www.rigicon.com\/es\/comunicados-de-prensa\/new-study-confirms-first-safety-outcomes-for-rigicon-conticlassic-artificial-urinary-sphincter-in-male-stress-urinary-incontinence-treatment\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Inicio","item":"https:\/\/www.rigicon.com\/es\/"},{"@type":"ListItem","position":2,"name":"Un nuevo estudio confirma los primeros resultados de seguridad para Rigicon ContiClassic\u00ae: Esf\u00ednter Urinario Artificial, en el tratamiento masculino Incontinencia Urinaria de Esfuerzo"}]},{"@type":"WebSite","@id":"https:\/\/www.rigicon.com\/es\/#website","url":"https:\/\/www.rigicon.com\/es\/","name":"Rigicon","description":"Innovative Urological Solutions","publisher":{"@id":"https:\/\/www.rigicon.com\/es\/#organization"},"alternateName":"Innovative Urological Solutions","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.rigicon.com\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es-ES"},{"@type":"Organization","@id":"https:\/\/www.rigicon.com\/es\/#organization","name":"Rigicon, Inc.","alternateName":"Innovative Urological Solutions","url":"https:\/\/www.rigicon.com\/es\/","logo":{"@type":"ImageObject","inLanguage":"es-ES","@id":"https:\/\/www.rigicon.com\/es\/#\/schema\/logo\/image\/","url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","contentUrl":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2024\/07\/cropped-Logo-Square-Kopya.jpg","width":512,"height":512,"caption":"Rigicon, Inc."},"image":{"@id":"https:\/\/www.rigicon.com\/es\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/rigiconurology\/","https:\/\/x.com\/rigiconurology","https:\/\/www.instagram.com\/rigiconurology\/","https:\/\/www.youtube.com\/@Rigicon\/podcasts","https:\/\/www.youtube.com\/Rigicon","https:\/\/www.threads.net\/@rigiconurology","https:\/\/www.linkedin.com\/company\/rigicon\/"],"description":"Rigicon is a global provider of innovative, diverse, and complete portfolio of prosthetic urology options.","email":"operations@rigicon.com","telephone":"+1 (888) 202-9790","legalName":"Rigicon, Inc.","vatID":"81-3545645","taxID":"81-3545645","duns":"045247683"}]}},"jetpack_featured_media_url":"https:\/\/www.rigicon.com\/wp-content\/uploads\/2023\/08\/press-releases-detail-page-classic-aus-d-1.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/posts\/13943","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/comments?post=13943"}],"version-history":[{"count":0,"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/posts\/13943\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/media\/1295"}],"wp:attachment":[{"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/media?parent=13943"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/categories?post=13943"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.rigicon.com\/es\/wp-json\/wp\/v2\/tags?post=13943"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}